Dr Mike Chapman
Position: Senior Research Associate
Personal home page: http://www.haem.cam.ac.uk/staff/senior-staff/dr-mike-chapman-2/
PubMed journal articles - click here
Dr Mike Chapman is pleased to consider applications from prospective PhD students.
Our long-term aim is to understand the interplay between the myriad pathways involved in the pathogenesis of multiple myeloma so that these can be targeted for therapeutic benefit. The initial focus of our research is the role of aberrant RNA processing in myeloma biology, based on findings from an initial sequencing of the myeloma genome (Chapman et al. Nature 2011) and subsequent myeloma genome sequencing projects. We are investigating not only the molecular mechanisms involved, but also the affected RNA targets, as these will identify nodes of intersection with known pathways as well as novel pathways in myeloma biology. Drawing on a wide experience in both molecular biology and bioinformatics, as well as extensive local expertise, we are applying a multidisciplinary approach, involving a number of cutting edge techniques. These will include molecular, cellular, genetic, structural, and genomic approaches and our work benefits from established local and international collaborations.
Co-immunoprecipitation Metabolic labelling of RNA RNA immunoprecipitation including iCLIP
Symplectic Elements feed provided by Research Information, University of Cambridge
Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet J, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BL, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siege lDS, Sivachenko A, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR (2011), Initial genome sequencing and analysis of multiple myeloma. Nature 2011 471(7339):467-72.